Allison Barraclough

528 total citations
29 papers, 152 citations indexed

About

Allison Barraclough is a scholar working on Pathology and Forensic Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Allison Barraclough has authored 29 papers receiving a total of 152 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Allison Barraclough's work include Lymphoma Diagnosis and Treatment (23 papers), CAR-T cell therapy research (13 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Allison Barraclough is often cited by papers focused on Lymphoma Diagnosis and Treatment (23 papers), CAR-T cell therapy research (13 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Allison Barraclough collaborates with scholars based in Australia, Canada and Denmark. Allison Barraclough's co-authors include Eliza A. Hawkes, Laurie H. Sehn, Diego Villa, Mark Bishton, Chan Y. Cheah, Geoffrey Chong, Sonali M. Smith, Leonid Churilov, Andrew Grigg and Colm Keane and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Allison Barraclough

21 papers receiving 152 citations

Peers

Allison Barraclough

PFM

ONCOL

NEURO

GENET

PRM

Joel Wight Australia

Anupkumar George Australia

Annalisa Peli Italy

Mu‐Chen Zhang China

Sarah Reinke Germany

Yazeed Sawalha United States

Christian Berdel Germany

David Šálek Czechia

Henry Jardel France

Chiara Lobetti‐Bodoni Switzerland

Joel Wight Australia

Allison Barraclough

104 ×1.0

PFM

58 ×0.7

ONCOL

43 ×1.2

NEURO

43 ×1.4

GENET

21 ×1.0

PRM

Citations per year, relative to Allison Barraclough Allison Barraclough (= 1×) peers Joel Wight

Countries citing papers authored by Allison Barraclough

Since Specialization

Citations

This map shows the geographic impact of Allison Barraclough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Barraclough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Barraclough more than expected).

Fields of papers citing papers by Allison Barraclough

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Barraclough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Barraclough. The network helps show where Allison Barraclough may publish in the future.

Co-authorship network of co-authors of Allison Barraclough

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Barraclough. A scholar is included among the top collaborators of Allison Barraclough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Barraclough. Allison Barraclough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barraclough, Allison, Sze Ting Lee, Melinda Burgess, et al.. (2025). Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study. Blood Advances. 9(6). 1432–1441.

Hawkes, Eliza A., Jodie Palmer, Richard Khor, et al.. (2025). T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial. Blood Advances. 9(20). 5263–5273.

Barraclough, Allison, Ilana Bar, Karin Fijnvandraat, et al.. (2025). Rewriting the script: gene therapy and genome editing for von Willebrand Disease. Frontiers in Genome Editing. 7. 1620438–1620438. 1 indexed citations

Wellard, Cameron, Allison Barraclough, Belinda A. Campbell, et al.. (2025). Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review. Blood Advances. 9(9). 2275–2284.

Lewis, Cameron, Allison Barraclough, & Eliza A. Hawkes. (2025). Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma. Blood. 145(17). 1850–1857.

Barraclough, Allison, et al.. (2025). Targeting synergetic endothelial inflammation by inhibiting NFKB and JAK-STAT pathways. iScience. 28(9). 113307–113307.

Barraclough, Allison & Eliza A. Hawkes. (2024). Predicting bispecific antibody failure in diffuse large B-cell lymphoma. Hematology. 2024(1). 318–320.

Chong, Geoffrey, Jodie Palmer, Allison Barraclough, et al.. (2024). First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.. Journal of Clinical Oncology. 42(16_suppl). TPS7092–TPS7092. 2 indexed citations

Bar, Ilana, Allison Barraclough, Petra E. Bürgisser, et al.. (2024). The severe von Willebrand disease variant p.M771V leads to impaired anterograde trafficking of von Willebrand factor in patient-derived and base-edited endothelial colony-forming cells. Journal of Thrombosis and Haemostasis. 23(2). 466–479. 2 indexed citations

10.

Barraclough, Allison, Catherine Tang, Masa Lasica, et al.. (2024). Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 55(1). 117–129.

11.

Lewis, Cameron, Paw Jensen, Allison Barraclough, et al.. (2024). Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study. British Journal of Haematology. 205(2). 534–541. 1 indexed citations

12.

Barraclough, Allison & Eliza A. Hawkes. (2023). Antibody and immunotherapy in diffuse large B-cell lymphoma. Seminars in Hematology. 60(5). 338–345. 3 indexed citations

13.

Chong, Geoffrey, Colm Keane, Sze-Ting Lee, et al.. (2023). Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia. 37(5). 1092–1102. 11 indexed citations

14.

Barraclough, Allison, Eliza A. Hawkes, Laurie H. Sehn, & Sonali M. Smith. (2023). Diffuse large B‐cell lymphoma. Hematological Oncology. 42(6). e3202–e3202. 13 indexed citations

15.

Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances. 3(13). 2013–2021. 28 indexed citations

16.

Hawkes, Eliza A., Jodie Palmer, Michael MacManus, et al.. (2019). Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. Blood. 134(Supplement_1). 5328–5328. 1 indexed citations

17.

Barraclough, Allison, Michael Gilbertson, Andrew Grigg, et al.. (2019). Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study. Blood. 134(Supplement_1). 1523–1523. 7 indexed citations

18.

Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2017). Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study. Blood. 130. 415–415.

19.

Barraclough, Allison, et al.. (2012). Brachial neuritis with phrenic nerve involvement. Journal of Clinical Neuroscience. 19(9). 1301–1302. 7 indexed citations

20.

Barraclough, Allison, et al.. (2011). Carotid body tumour. ANZ Journal of Surgery. 81(12). 934–935. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact